Will The Magnificent 7 Stocks Go Up This Year?
2025 was another banner year for the Magnificent Seven stocks,…
Buy
73
BEAM Quote, Financials, Valuation and Earnings
Last price:
$27.51
Seasonality move
:
-23.84%
Day range:
$27.29 - $28.71
52-week range:
$13.53 - $35.25
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
46.41x
P/B ratio:
2.89x
Volume:
1.2M
Avg. volume:
1.6M
1-year change:
2.8%
Market cap:
$2.8B
Revenue:
$63.5M
EPS (TTM):
-$4.43
Analysts' Opinion
-
Consensus RatingBeam Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 13 Buy ratings, 3 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $45.20, Beam Therapeutics, Inc. has an estimated upside of 64.07% from its current price of $27.55.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $21.00 representing 23.78% downside risk from its current price of $27.55.
Fair Value
-
According to the consensus of 16 analysts, Beam Therapeutics, Inc. has 64.07% upside to fair value with a price target of $45.20 per share.
BEAM vs. S&P 500
-
Over the past 5 trading days, Beam Therapeutics, Inc. has underperformed the S&P 500 by -0.06% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Beam Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Beam Therapeutics, Inc. revenues have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Beam Therapeutics, Inc. reported revenues of $9.7M.
Earnings Growth
-
Beam Therapeutics, Inc. has grown year-over-year earnings for 2 quarters straight. In the most recent quarter Beam Therapeutics, Inc. reported earnings per share of -$1.10.
Enterprise value:
1.9B
EV / Invested capital:
--
Price / LTM sales:
46.41x
EV / EBIT:
--
EV / Revenue:
33.61x
PEG ratio (5yr expected):
-0.04x
EV / Free cash flow:
-5.31x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$33.6M
Return On Assets:
-32.17%
Net Income Margin (TTM):
-744.41%
Return On Equity:
-44.48%
Return On Invested Capital:
-38.05%
Operating Margin:
-1307.6%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $81.6M | $349.6M | $55.7M | $14.3M | $9.7M | |
| Gross Profit | $53.6M | $327.8M | $33.6M | $8.8M | $4.1M | |
| Operating Income | -$398.3M | -$182.7M | -$466.3M | -$106.5M | -$126.8M | |
| EBITDA | -$370.4M | -$160.8M | -$444.2M | -$101M | -$121.3M | |
| Diluted EPS | -$4.18 | -$1.76 | -$4.43 | -$1.17 | -$1.10 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $941.4M | $1.1B | $1B | $945.5M | $1.1B | |
| Total Assets | $1.2B | $1.4B | $1.3B | $1.2B | $1.3B | |
| Current Liabilities | $101.4M | $238.9M | $220.4M | $166.2M | $182.6M | |
| Total Liabilities | $302.7M | $635.8M | $511.6M | $380.1M | $345.1M | |
| Total Equity | $853.8M | $714.5M | $778.9M | $791.3M | $966M | |
| Total Debt | $139M | $168.7M | $162M | $149.1M | $138.7M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$353.5M | -$135.8M | -$338.2M | -$88.1M | -$81.5M | |
| Cash From Investing | $87.2M | $156.8M | -$103.6M | $24.7M | $65.7M | |
| Cash From Financing | $274.7M | $38M | $479.6M | $1.3M | $1.7M | |
| Free Cash Flow | -$391.9M | -$145.4M | -$352.4M | -$89.7M | -$86.5M | |
BEAM
Sector
Market Cap
$2.8B
$28.1M
Price % of 52-Week High
78.16%
51.87%
Dividend Yield
0%
0%
Shareholder Yield
-19.38%
-1.59%
1-Year Price Total Return
2.8%
-17.31%
Beta (5-Year)
2.070
0.495
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$27.88
200-day SMA
Buy
Level
$21.17
Bollinger Bands (100)
Buy
Level
20.31 - 27.63
Chaikin Money Flow
Sell
Level
-37.6M
20-day SMA
Buy
Level
$27.45
Relative Strength Index (RSI14)
Buy
Level
53.41
ADX Line
Buy
Level
25.75
Williams %R
Neutral
Level
-68.0507
50-day SMA
Buy
Level
$25.28
MACD (12, 26)
Buy
Level
0.70
25-day Aroon Oscillator
Buy
Level
48
On Balance Volume
Neutral
Level
40.7M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (0.9458)
Sell
CA Score
(Annual)
Level (-1.1323)
Buy
Beneish M-Score
(Annual)
Level (-5.0092)
Buy
Momentum Score
Level (4)
Sell
Ohlson Score
Level (0.8564)
Sell
Piotroski F Score
(Annual)
Level (3)
Sell
Quality Ratio Score
Level (4)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.
Stock Forecast FAQ
In the current month, BEAM has received 13 Buy ratings 3 Hold ratings, and 0 Sell ratings. The BEAM average analyst price target in the past 3 months is $45.20.
-
Where Will Beam Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Beam Therapeutics, Inc. share price will rise to $45.20 per share over the next 12 months.
-
What Do Analysts Say About Beam Therapeutics, Inc.?
Analysts are divided on their view about Beam Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Beam Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $21.00.
-
What Is Beam Therapeutics, Inc.'s Price Target?
The price target for Beam Therapeutics, Inc. over the next 1-year time period is forecast to be $45.20 according to 16 Wall Street analysts, 13 of them rate the stock a Buy, 0 rate the stock a Sell, and 3 analysts rate the stock a Hold.
-
Is BEAM A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Beam Therapeutics, Inc. is a Buy. 13 of 16 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of BEAM?
You can purchase shares of Beam Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Beam Therapeutics, Inc. shares.
-
What Is The Beam Therapeutics, Inc. Share Price Today?
Beam Therapeutics, Inc. was last trading at $27.51 per share. This represents the most recent stock quote for Beam Therapeutics, Inc.. Yesterday, Beam Therapeutics, Inc. closed at $27.55 per share.
-
How To Buy Beam Therapeutics, Inc. Stock Online?
In order to purchase Beam Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get BEAM Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
BEAM
Sector
P/E ratio
--
24.20x
PEG ratio
-0.04x
-0.01x
P/B ratio
2.89x
1.84x
Price / LTM sales
46.41x
1.60x
Growth Metrics
BEAM
Sector
Revenue growth
-32.04%
4.51%
Earnings growth
6.31%
10.7%
Revenue (5-year growth)
412.3%
6.45%
Earnings forecast
-$1.12
-$0.19
Profitability
BEAM
Sector
Profitability FY 2024
$41.6M
$3.5M
Return on invested capital
-38.05%
-32.3%
Return on assets
-32.17%
-28.57%
Return on equity
-44.48%
-38.09%
Earnings Date
Last Earnings Date
Nov
4
Next Earnings Date
Feb
24
Estimated Next Earnings Date
Feb
3
Balance Sheet
BEAM
Sector
Total cash
$1.1B
$26M
Short term investments
$568.8M
$25.7M
Total assets
$1.1B
$76.4M
Long term debt
$138.7M
$3.2M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Planet Labs Stock Rally So Much?
Satellite imaging startup Planet Labs (NYSE:PL), after years of disappointing…
Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
100
ATGL alert for Jan 10
Alpha Technology Group Ltd. [ATGL] is up 47.05% over the past day.
Buy
71
NAIL alert for Jan 10
Direxion Daily Homebuilders & Supplies Bull 3X Shs [NAIL] is up 18.52% over the past day.
Buy
54
LGIH alert for Jan 10
LGI Homes, Inc. [LGIH] is up 13.81% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
